Endometrial Cancer Market

Executive Summary

Endometrial Cancer Market was valued at US $4,418.52 million in 2021 and is projected to grow at 8.33% CAGR over the forecast period to reach US $7,140.15 million by 2027. Endometrial Cancer Market represented US $653.22 million opportunity over 2019-2021 and estimated to create US $2,721.63 million opportunity in 2027 over 2021.

Endometrial Cancer from Consainsights analyses the Endometrial Cancer Market in the Life Sciences industry over the forecast period to 2027.

Endometrial Cancer research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Endometrial Cancer segmentation includes Type of Cancer, Type of Therapy, Diagnosis Method and Geography.

Based on the Type of Cancer, the Endometrial Cancer analysis covers Endometrial Carcinoma, Uterine Sarcomas.

In Type of Cancer segment, Endometrial Carcinoma segment has highest cagr growth of 7.37%.

Based on the Type of Therapy, the Endometrial Cancer analysis covers Immunotherapy, Radiation Therapy, Chemotherapy, Other Types of Therapies.

In Type of Therapy segment, Immunotherapy segment has highest cagr growth of 7.37%.

Based on the Diagnosis Method, the Endometrial Cancer analysis covers Biopsy, Pelvic Ultrasound, Hysteroscopy, CT Scan, Other Diagnosis Methods.

In Diagnosis Method segment, Biopsy segment has highest cagr growth of 7.37%.

Based on the region, the Endometrial Cancer analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Merck & Co., Inc., Mylan, Eisai Co., Ltd., Novartis AG, R-Pharm-US LLC., Pfizer Inc., Elekta AB, Varian Medical Systems, Inc. and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Type of Cancer

Introduction

In 2021, Endometrial Carcinoma segment has the highest revenue of US $2,851.52 million and is expected to grow at CAGR of 7.37% by 2027 Endometrial Carcinoma segment has highest cagr growth of 7.37%.

Endometrial Carcinoma

Endometrial Carcinoma segment was valued at US $2,429.96 million in 2019 and is projected to grow at 7.37% CAGR over the forecast period to reach US $4,607.94 million by 2027. Endometrial Carcinoma segment represented US $421.56 million opportunity over 2019-2021 and estimated to create US $1,756.42 million opportunity in 2027 over 2021.

Uterine Sarcomas

Uterine Sarcomas segment was valued at US $1,335.34 million in 2019 and is projected to grow at 7.37% CAGR over the forecast period to reach US $2,532.21 million by 2027. Uterine Sarcomas segment represented US $231.66 million opportunity over 2019-2021 and estimated to create US $965.21 million opportunity in 2027 over 2021.

Type of Therapy

Introduction

In 2021, Immunotherapy segment has the highest revenue of US $1,751.95 million and is expected to grow at CAGR of 7.37% by 2027 Immunotherapy segment has highest cagr growth of 7.37%.

Immunotherapy

Immunotherapy segment was valued at US $1,492.95 million in 2019 and is projected to grow at 7.37% CAGR over the forecast period to reach US $2,831.08 million by 2027. Immunotherapy segment represented US $259.00 million opportunity over 2019-2021 and estimated to create US $1,079.13 million opportunity in 2027 over 2021.

Radiation Therapy

Radiation Therapy segment was valued at US $1,343.61 million in 2019 and is projected to grow at 7.37% CAGR over the forecast period to reach US $2,547.90 million by 2027. Radiation Therapy segment represented US $233.09 million opportunity over 2019-2021 and estimated to create US $971.19 million opportunity in 2027 over 2021.

Chemotherapy

Chemotherapy segment was valued at US $872.59 million in 2019 and is projected to grow at 7.37% CAGR over the forecast period to reach US $1,654.69 million by 2027. Chemotherapy segment represented US $151.38 million opportunity over 2019-2021 and estimated to create US $630.72 million opportunity in 2027 over 2021.

Other Types of Therapies

Other Types of Therapies segment was valued at US $56.15 million in 2019 and is projected to grow at 7.37% CAGR over the forecast period to reach US $106.48 million by 2027. Other Types of Therapies segment represented US $9.74 million opportunity over 2019-2021 and estimated to create US $40.59 million opportunity in 2027 over 2021.

Diagnosis Method

Introduction

In 2021, Biopsy segment has the highest revenue of US $1,678.79 million and is expected to grow at CAGR of 7.37% by 2027 Biopsy segment has highest cagr growth of 7.37%.

Biopsy

Biopsy segment was valued at US $1,430.60 million in 2019 and is projected to grow at 7.37% CAGR over the forecast period to reach US $2,712.85 million by 2027. Biopsy segment represented US $248.19 million opportunity over 2019-2021 and estimated to create US $1,034.06 million opportunity in 2027 over 2021.

Pelvic Ultrasound

Pelvic Ultrasound segment was valued at US $1,003.40 million in 2019 and is projected to grow at 7.37% CAGR over the forecast period to reach US $1,902.74 million by 2027. Pelvic Ultrasound segment represented US $174.07 million opportunity over 2019-2021 and estimated to create US $725.27 million opportunity in 2027 over 2021.

Hysteroscopy

Hysteroscopy segment was valued at US $641.49 million in 2019 and is projected to grow at 7.37% CAGR over the forecast period to reach US $1,216.47 million by 2027. Hysteroscopy segment represented US $111.29 million opportunity over 2019-2021 and estimated to create US $463.68 million opportunity in 2027 over 2021.

CT Scan

CT Scan segment was valued at US $438.77 million in 2019 and is projected to grow at 7.37% CAGR over the forecast period to reach US $832.04 million by 2027. CT Scan segment represented US $76.12 million opportunity over 2019-2021 and estimated to create US $317.15 million opportunity in 2027 over 2021.

Other Diagnosis Methods

Other Diagnosis Methods segment was valued at US $251.04 million in 2019 and is projected to grow at 7.37% CAGR over the forecast period to reach US $476.05 million by 2027. Other Diagnosis Methods segment represented US $43.55 million opportunity over 2019-2021 and estimated to create US $181.46 million opportunity in 2027 over 2021.